Oculis Holding Management

Management criteria checks 0/4

Oculis Holding's CEO is Riad Sherif, appointed in Dec 2017, has a tenure of 6.5 years. directly owns 2.1% of the company’s shares, worth €9.62M. The average tenure of the management team and the board of directors is 1.6 years and 1.6 years respectively.

Key information

Riad Sherif

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	6.5yrs
CEO ownership	2.1%
Management average tenure	1.6yrs
Board average tenure	1.6yrs

Recent management updates

Recent updates

CEO

Riad Sherif (56 yo)

6.5yrs

Tenure

Dr. Riad Sherif, MD, MBA, has been the Chief Executive Officer and Director of Oculis Holding AG (formerly known as Oculis SA) since December 2017. He is Chief Executive Officer and Director of Oculis ehf....

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Riad Sherif	CEO & Director	6.5yrs	no data	2.1% CHF 9.6m
Sylvia Cheung	Chief Financial Officer	3.8yrs	no data	0.16% CHF 731.6k
Ramin Tadayoni	Chief Scientific Officer	less than a year	no data	no data
Virginia Dean	Chief Human Resources Officer	less than a year	no data	no data
Bastian Dehmel	Chief Development Officer	2.4yrs	no data	no data
Páll Jóhannesson	Chief Business Officer	3.8yrs	no data	0.60% CHF 2.7m
Rebecca Weil	Chief Commercial Officer	less than a year	no data	no data
Snehal Shah	President of Research & Development	less than a year	no data	no data

1.6yrs

Average Tenure

53yo

Average Age

Experienced Management: CR5's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Riad Sherif	CEO & Director	6.5yrs	no data	2.1% CHF 9.6m
Eric Donnenfeld	Chair of Cornea Scientific Advisory Board	no data	no data	no data
Anthony Rosenberg	Independent Chairman	6.2yrs	no data	0.23% CHF 1.1m
Christophe Baudouin	Member of Scientific Advisory Board	1.6yrs	no data	no data
Peter Kaiser	Member of Scientific Advisory Board	1.6yrs	no data	no data
Lionel Carnot	Independent Director	6.5yrs	no data	no data
Christina Ackermann	Independent Director	1.3yrs	no data	0.028% CHF 128.3k
Quan Dong Nguyen	Member of Scientific Advisory Board	1.6yrs	no data	no data
Robert Warner	Director	less than a year	no data	no data
Arshad Khanani	Chair of Retina Scientific Advisory Board & Director	1.6yrs	no data	no data
Anat Loewenstein	Member of Scientific Advisory Board	1.6yrs	no data	no data
Pablo Villoslada	Member of Scientific Advisory Board	1.6yrs	no data	no data

1.6yrs

Average Tenure

59yo

Average Age

Experienced Board: CR5's board of directors are not considered experienced ( 1.6 years average tenure), which suggests a new board.

Oculis Holding Management

Management criteria checks 0/4

Key information

Recent management updates

Oculis Holding AG Announces Board and Committee Appointments

Oculis Holding AG, Annual General Meeting, May 29, 2024

Oculis Holding AG Strengthens its Executive Leadership Team with the Appointment of Snehal Shah as President of Research & Development

Oculis Holding AG Appoints Rebecca Weil as Chief Commercial Officer

High number of new directors

High number of new directors

Recent updates

Oculis Holding AG Announces Positive Topline Results of Phase 2b RelieF Trial with Licaminlimab Designed to Transform the Treatment Paradigm of Dry Eye Disease with a Precision Medicine Strategy

Oculis Holding AG Announces Board and Committee Appointments

First quarter 2024 earnings released: CHF0.44 loss per share (vs CHF1.27 loss in 1Q 2023)

Oculis Holding AG has filed a Follow-on Equity Offering in the amount of $100 million.

Oculis Holding AG, Annual General Meeting, May 29, 2024

Oculis Holding AG has completed a Follow-on Equity Offering in the amount of $58.75 million.

Oculis Holding AG has filed a Follow-on Equity Offering in the amount of $58.75 million.

Oculis Holding AG Strengthens its Executive Leadership Team with the Appointment of Snehal Shah as President of Research & Development

Oculis Holding Ag Announces Positive Results from Phase 3 Optimize-1 Trial of Once Daily Ocs-01 for the Treatment of Inflammation and Pain Following Cataract Surgery

Full year 2023 earnings released: CHF2.97 loss per share (vs CHF12.95 loss in FY 2022)

New major risk - Revenue and earnings growth

Oculis Announces First Patient First Visit in Phase 3 OPTIMIZE-2 Trial of OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery

Oculis Holding AG Announces First Patient First Visit in Phase 3 DIAMOND-1 Trial of OCS-01 Eye Drop in Diabetic Macular Edema

Oculis Announces First Patient First Visit in Phase 2b RELIEF Trial of Topical Anti-TNF ALPHA> Licaminlimab (OCS-02) in Dry Eye Disease

Third quarter 2023 earnings released: CHF0.48 loss per share (vs CHF3.29 loss in 3Q 2022)

Oculis Holding AG announced that it has received $71.18891 million in funding from a group of investors

Oculis Holding AG Announces Positive Phase 3 Stage 1 Diamond Trial Results of OCS-01 in Diabetic Macular Edema Presented at 23rd EURETINA Congress

Oculis Holding to Present Late-Breaking Abstract at the 23rd EURETINA Congress on Positive Phase 3 Stage 1 Diamond Trial Results for Diabetic Macular Edema

New major risk - Revenue and earnings growth

Oculis Holding AG Appoints Rebecca Weil as Chief Commercial Officer

Second quarter 2023 earnings released: CHF0.38 loss per share (vs CHF3.29 loss in 2Q 2022)

Oculis Holding Ag Announces Positive Top Line Results from Its Phase 3 Optimize Trial with Ocs-01 Eye Drops

High number of new directors

Oculis Holding AG to Host an R&D Retina Day to Showcase Clinical Programs Targeting Diabetic Macular Edema and Other Retina Diseases

High number of new directors

CEO

Tenure

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age